Lifecore Biomedical (LFCR) financial statements
Lifecore Biomedical reported revenue of $129M in fiscal 2025, down 13.5% a year over 9 years.
Net income was -$39M and the operating margin -13.4%, against -4.3% in 2016.
Free cash flow was -$14M.
The diluted share count rose 29% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Lifecore Biomedical's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $477M | $470M | $524M | $558M | $160M | $101M | $111M | $103M | $128M | $129M |
| Cost of revenue | $410M | $391M | $446M | $477M | $121M | $62M | $72M | $75M | $86M | $89M |
| Gross profit | $67M | $79M | $78M | $81M | $39M | $39M | $39M | $28M | $42M | $40M |
| Research and development | $7M | $9M | $13M | $11M | $8M | $7M | $8M | $9M | $9M | $8M |
| Selling, general and admin | $46M | $52M | $52M | $62M | $41M | $28M | $35M | $39M | $40M | $44M |
| Operating income | -$21M | $15M | $14M | $5M | -$26M | -$9M | -$12M | -$22M | -$9M | -$17M |
| Interest expense | $2M | — | — | — | $5M | $9M | $16M | $18M | $18M | $22M |
| Pre-tax income | -$20M | $14M | $16M | $4M | -$31M | -$30M | -$21M | -$64M | $10M | -$39M |
| Income tax | -$8M | $4M | -$9M | $2M | -$9M | -$6M | -$5M | $308,000 | $183,000 | $43,000 |
| Net income | -$12M | $11M | $25M | $411,000 | -$38M | -$32M | -$117M | -$100M | $12M | -$39M |
| EPS (diluted) | -$0.43 | $0.38 | $0.89 | $0.01 | -$1.31 | -$1.10 | -$3.97 | -$3.32 | $0.33 | -$1.27 |
| Diluted shares | 27M | 28M | 28M | 29M | 29M | 29M | 29M | 30M | 37M | 35M |
| Gross margin | 14.0% | 16.9% | 14.9% | 14.5% | 24.6% | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% |
| Operating margin | -4.3% | 3.1% | 2.6% | 1.0% | -16.2% | -8.7% | -10.6% | -21.1% | -6.9% | -13.4% |
| Net margin | -2.4% | 2.3% | 4.7% | 0.1% | -23.9% | -32.0% | -104.9% | -96.4% | 9.4% | -30.0% |
Balance sheet
Fiscal years, from Lifecore Biomedical's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $10M | $6M | $3M | $1M | $360,000 | $763,000 | $991,000 | $19M | $8M | $8M |
| Receivables | $46M | $46M | $54M | $70M | $76M | $32M | $38M | $29M | $31M | — |
| Inventory | $26M | $24M | $32M | $54M | $66M | $34M | $36M | $41M | $40M | $32M |
| Total current assets | $86M | $81M | $97M | $133M | $157M | $145M | $117M | $94M | $81M | $86M |
| Property, plant and equipment | $121M | $133M | $160M | $200M | $192M | $107M | $119M | $134M | $149M | $129M |
| Goodwill | $50M | $55M | $55M | $77M | $34M | $14M | $14M | $14M | $14M | $14M |
| Total assets | $343M | $359M | $405M | $519M | $294M | $502M | $275M | $254M | $254M | $239M |
| Total current liabilities | $56M | $51M | $88M | $137M | $164M | $102M | $177M | $39M | $39M | $30M |
| Long-term debt | $46M | $42M | $37M | $87M | $101M | $165M | $0 | $84M | $101M | — |
| Total liabilities | $130M | $130M | $152M | $249M | $310M | $300M | $187M | $218M | $200M | $192M |
| Shareholders' equity | $211M | $227M | $253M | $270M | $230M | $202M | $88M | -$4M | $11M | $1M |
| Net debt | $44M | $41M | $39M | $96M | $113M | $164M | $97M | $66M | $93M | -$5M |
Cash flow
Fiscal years, from Lifecore Biomedical's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $21M | $30M | $20M | $16M | -$17M | $16M | -$23M | -$17M | $257,000 | -$206,000 |
| Capital spending | $40M | $23M | $34M | $45M | $27M | $24M | $26M | $21M | $18M | $13M |
| Free cash flow | -$19M | $7M | -$14M | -$29M | -$44M | -$7M | -$49M | -$39M | -$18M | -$14M |
| Stock-based compensation | $3M | $4M | $4M | $4M | $2M | $3M | $3M | $4M | $6M | $10M |
| Net borrowing | $12M | -$7M | -$5M | $55M | $16M | $56M | -$66M | $26M | $0 | — |
| Free cash flow margin | -4.0% | 1.5% | -2.6% | -5.1% | -27.3% | -7.2% | -43.9% | -37.7% | -14.1% | -10.6% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LFCR.
Open LFCR in InvestinglyQuestions
What was Lifecore Biomedical's revenue in 2025?
$129M in fiscal 2025, from its 10-K filing.
How much free cash flow does Lifecore Biomedical generate?
-$14M in fiscal 2025 (operating cash flow minus capital spending).
From Lifecore Biomedical's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.